Last reviewed · How we verify

Kang Stem Biotech Co., Ltd. — Portfolio Competitive Intelligence Brief

Kang Stem Biotech Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
FURESTEM-AD Inj. FURESTEM-AD Inj. phase 3 Allogeneic mesenchymal stem cell therapy Dermatology / Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Anterogen Co., Ltd. · 1 shared drug class
  2. Cell Biopeutics Resources Sdn Bhd · 1 shared drug class
  3. Medipost, Inc. · 1 shared drug class
  4. Mesoblast, Ltd. · 1 shared drug class
  5. Pharmicell Co., Ltd. · 1 shared drug class
  6. Tigenix S.A.U. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kang Stem Biotech Co., Ltd.:

Cite this brief

Drug Landscape (2026). Kang Stem Biotech Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kang-stem-biotech-co-ltd. Accessed 2026-05-16.

Related